{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:46:49Z","timestamp":1791935209605,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62575109"],"award-info":[{"award-number":["62575109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62305121"],"award-info":[{"award-number":["62305121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373104"],"award-info":[{"award-number":["82373104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncolytic bacteria are microorganisms with cytotoxic activity capable of lysing cancer cells while simultaneously activating both innate and adaptive immune responses to exert anti-tumor effects. However, the innate immune activation targeting oncolytic bacteria within the tumor microenvironment (TME) is a limiting factor. Here we find that the CD11b-targeting agonist GB1275 can modulate bacteria-immune interaction and inhibit the infiltration of CD11b\u207a innate immune cells such as neutrophils and macrophages, thereby suppressing the antimicrobial immune defenses in the TME in mice. This then avoids the clearance of oncolytic bacteria and increases the efficacy of bacteria-mediated tumor immunotherapy. Furthermore, the gemcitabine-loaded bacteria combined with GB1275 treatment activate innate immune responses in tumor, as mediated by Toll-like receptors (TLR), NOD-like receptors (NLR) and cGAS-STING pathways, while simultaneously enhancing dendritic cell (DC)-dependent antigen cross-presentation; this then upregulates the adaptive anti-tumor immune response and inhibits the growth of both subcutaneous and in situ pancreatic cancers in mouse tumor models. Our results therefore demonstrate that modulating innate immune responses while subsequently strengthening adaptive immune activation can significantly improve the efficacy of bacteria-mediated tumor immunotherapy.<\/jats:p>","DOI":"10.1038\/s41467-026-76823-7","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:07:30Z","timestamp":1787324850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD11b agonist GB1275 potentiates oncolytic bacterial therapy against pancreatic cancer in mouse tumor models"],"prefix":"10.1038","volume":"17","author":[{"given":"Bin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ting","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-3465","authenticated-orcid":false,"given":"Kai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4286-4275","authenticated-orcid":false,"given":"Yuan-Di","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5450-5528","authenticated-orcid":false,"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8434-7591","authenticated-orcid":false,"given":"Jin-Xuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2171-9279","authenticated-orcid":false,"given":"Qiu-Ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"76823_CR1","doi-asserted-by":"publisher","first-page":"249ra111","DOI":"10.1126\/scitranslmed.3008982","volume":"6","author":"NJ Roberts","year":"2014","unstructured":"Roberts, N. J. et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci. Transl. Med. 6, 249ra111 (2014).","journal-title":"Sci. Transl. Med."},{"key":"76823_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","volume":"14","author":"WB Coley","year":"1891","unstructured":"Coley, W. B. Contribution to the knowledge of sarcoma. Ann. Surg. 14, 199\u2013220 (1891).","journal-title":"Ann. Surg."},{"key":"76823_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58289-1","volume":"16","author":"IH Murillo","year":"2025","unstructured":"Murillo, I. H. et al. Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse. Nat. Commun. 16, 3369 (2025).","journal-title":"Nat. Commun."},{"key":"76823_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2020.09.058","volume":"183","author":"L Kalafati","year":"2020","unstructured":"Kalafati, L. et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell 183, 771\u2013785 (2020).","journal-title":"Cell"},{"key":"76823_CR5","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/s41591-025-03698-4","volume":"31","author":"LP Chen","year":"2025","unstructured":"Chen, L. P. PD-L1 and the dawn of modern cancer immunotherapy. Nat. Med. 31, 1387 (2025).","journal-title":"Nat. Med."},{"key":"76823_CR6","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"CS Qi","year":"2025","unstructured":"Qi, C. S. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. LANCET 405, 2020\u20132049 (2025).","journal-title":"LANCET"},{"key":"76823_CR7","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1016\/j.cell.2024.10.016","volume":"187","author":"F Lin","year":"2024","unstructured":"Lin, F. et al. Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell 187, 7470\u20137491 (2024).","journal-title":"Cell"},{"key":"76823_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng, L. et al. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell. Mol. Immunol. 21, 1089\u20131108 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"76823_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim, T. K. et al. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21, 529\u2013540 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"76823_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41586-024-08033-4","volume":"635","author":"A Redenti","year":"2024","unstructured":"Redenti, A. et al. Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature 635, 453\u2013461 (2024).","journal-title":"Nature"},{"key":"76823_CR11","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1126\/science.add9667","volume":"378","author":"CR Gurbatri","year":"2022","unstructured":"Gurbatri, C. R. et al. Engineering bacteria as interactive cancer therapies. Science 378, 858\u2013864 (2022).","journal-title":"Science"},{"key":"76823_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adn9879","volume":"9","author":"FD Li","year":"2024","unstructured":"Li, F. D. et al. Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms. Sci. Immunol. 9, eadn9879 (2024).","journal-title":"Sci. Immunol."},{"key":"76823_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s44222-023-00119-4","volume":"2","author":"J Hahn","year":"2024","unstructured":"Hahn, J. et al. Bacterial therapies at the interface of synthetic biology and nanomedicine. Nat. Rev. Bioeng. 2, 120\u2013135 (2024).","journal-title":"Nat. Rev. Bioeng."},{"key":"76823_CR14","doi-asserted-by":"publisher","first-page":"eadt7298","DOI":"10.1126\/sciadv.adt7298","volume":"11","author":"XT Xie","year":"2025","unstructured":"Xie, X. T. et al. Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy. Sci. Adv. 11, eadt7298 (2025).","journal-title":"Sci. Adv."},{"key":"76823_CR15","doi-asserted-by":"publisher","first-page":"1808278","DOI":"10.1002\/adma.201808278","volume":"31","author":"JX Fan","year":"2019","unstructured":"Fan, J. X. et al. Engineered bacterial bioreactor for tumor therapy via fenton-like reaction with localized H2O2 generation. Adv. Mater. 31, 1808278 (2019).","journal-title":"Adv. Mater."},{"key":"76823_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-024-00908-9","volume":"21","author":"SY Kwon","year":"2024","unstructured":"Kwon, S. Y. et al. Exploiting bacteria for cancer immunotherapy. Nat. Rev. Clin. Oncol. 21, 569\u2013589 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76823_CR17","first-page":"1","volume":"58","author":"JC Castillo","year":"2025","unstructured":"Castillo, J. C. et al. Cellular mechanisms underlying beneficial versus detrimental effects of bacterial antitumor immunotherapy. Immunity 58, 1\u201317 (2025).","journal-title":"Immunity"},{"key":"76823_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41551-024-01191-w","volume":"8","author":"CY Wang","year":"2024","unstructured":"Wang, C. Y. et al. Oncolytic mineralized bacteria as potent locally administered immunotherapeutics. Nat. Biomed. Eng. 8, 561\u2013578 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"76823_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.canlet.2019.01.037","volume":"448","author":"K Liang","year":"2019","unstructured":"Liang, K. et al. Genetically engineered salmonella typhimurium: Recent advances in cancer therapy. Cancer Lett. 448, 168\u2013181 (2019).","journal-title":"Cancer Lett."},{"key":"76823_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s43018-023-00658-0","volume":"5","author":"LJ Zhao","year":"2024","unstructured":"Zhao, L. J. et al. Bacterial cytolysin induces mitochondrial DNA release to activate cGAS-STING pathway and enhance immunotherapy. Nat. Cancer 5, 147\u2013166 (2024).","journal-title":"Nat. Cancer"},{"key":"76823_CR21","first-page":"640","volume":"21","author":"BK Sing","year":"2023","unstructured":"Sing, B. K. et al. Listeriolysin O: A key player in the immune response to Listeria monocytogenes. FEMS Microbiol. Rev. 21, 640\u2013656 (2023).","journal-title":"FEMS Microbiol. Rev."},{"key":"76823_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.canlet.2019.10.033","volume":"469","author":"YX Guo","year":"2020","unstructured":"Guo, Y. X. et al. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium. Cancer Lett. 469, 102\u2013110 (2020).","journal-title":"Cancer Lett."},{"key":"76823_CR23","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-07-2984","volume":"68","author":"K Westphal","year":"2008","unstructured":"Westphal, K. et al. Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res. 68, 2952\u20132960 (2008).","journal-title":"Cancer Res."},{"key":"76823_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1021\/acs.nanolett.0c03811","volume":"21","author":"Z Mi","year":"2021","unstructured":"Mi, Z. et al. \u201cTrojan Horse\u201d salmonella enabling tumor homing of silver nanoparticles via neutrophil infiltration for synergistic tumor therapy and enhanced biosafety. Nano Lett. 21, 414\u2013423 (2021).","journal-title":"Nano Lett."},{"key":"76823_CR25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-025-08629-4","volume":"640","author":"J Lesbats","year":"2025","unstructured":"Lesbats, J. et al. Macrophages recycle phagocytosed bacteria to fuel immunometabolic responses. Nature 640, 524\u2013533 (2025).","journal-title":"Nature"},{"key":"76823_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2101","volume":"7","author":"AJ Monteith","year":"2021","unstructured":"Monteith, A. J. et al. Neutrophil extracellular traps enhance macrophage killing of bacterial pathogens. Sci. Adv. 7, eabj2101 (2021).","journal-title":"Sci. Adv."},{"key":"76823_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2021.104693","volume":"86","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Lovastatin suppresses bacterial therapy-induced neutrophil recruitment to the tumor by promoting neutrophil apoptosis. J. Funct. Foods 86, 104693 (2021).","journal-title":"J. Funct. Foods"},{"key":"76823_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11390-8","volume":"10","author":"ZP Cao","year":"2019","unstructured":"Cao, Z. P. et al. Camouflaging bacteria by wrapping with cell membranes. Nat. Commun. 10, 3452 (2019).","journal-title":"Nat. Commun."},{"key":"76823_CR29","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1021\/acsmaterialslett.5c00012","volume":"7","author":"B Zhang","year":"2025","unstructured":"Zhang, B. et al. Camouflaging attenuated salmonella by detachable metal polyphenol nanoshells for enhanced bacteria-based cancer immunotherapy. ACS Mater. Lett. 7, 1593\u20131602 (2025).","journal-title":"ACS Mater. Lett."},{"key":"76823_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cell.2025.02.002","volume":"188","author":"ZG Chang","year":"2025","unstructured":"Chang, Z. G. et al. Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization. Cell 188, 1\u201316 (2025).","journal-title":"Cell"},{"key":"76823_CR31","first-page":"189ra57","volume":"4","author":"M Dony","year":"2021","unstructured":"Dony, M. et al. Small molecule-mediated activation of the integrin CD11b\/CD18 reduces inflammatory disease. Sci. Signal. 4, 189ra57 (2021).","journal-title":"Sci. Signal."},{"key":"76823_CR32","doi-asserted-by":"publisher","first-page":"eaau9240","DOI":"10.1126\/scitranslmed.aau9240","volume":"11","author":"RZ Panni","year":"2019","unstructured":"Panni, R. Z. et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Sci. Transl. Med. 11, eaau9240 (2019).","journal-title":"Sci. Transl. Med."},{"key":"76823_CR33","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ccell.2023.04.018","volume":"41","author":"XT Liu","year":"2023","unstructured":"Liu, X. T. et al. Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer Cell 41, 1073\u2013-1090 (2023).","journal-title":"Cancer Cell"},{"key":"76823_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07387-4","volume":"9","author":"MC Schmid","year":"2018","unstructured":"Schmid, M. C. et al. Integrin CD11b activation drives anti-tumor innate immunity. Nat. Commun. 9, 5379 (2018).","journal-title":"Nat. Commun."},{"key":"76823_CR35","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1200\/JCO.2020.38.15_suppl.3085","volume":"38","author":"DW Rasco","year":"2022","unstructured":"Rasco, D. W. et al. A phase I\/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36). J. Clin. Oncol. 38, 3085 (2022).","journal-title":"J. Clin. Oncol."},{"key":"76823_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JCO.2002.20.1.142","volume":"20","author":"JF Toso","year":"2002","unstructured":"Toso, J. F. et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20, 142\u201352 (2002).","journal-title":"J. Clin. Oncol."},{"key":"76823_CR37","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","volume":"303","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532\u20131535 (2004).","journal-title":"Science"},{"key":"76823_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq6399","volume":"11","author":"HR An","year":"2025","unstructured":"An, H. R. et al. Splenic red pulp macrophages eliminate the liver-resistant Streptococcus pneumoniae from the blood circulation of mice. Sci. Adv. 11, eadq6399 (2025).","journal-title":"Sci. Adv."},{"key":"76823_CR39","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41596-022-00723-5","volume":"17","author":"T Harimoto","year":"2022","unstructured":"Harimoto, T. et al. A rapid screening platform to coculture bacteria within tumor spheroids. Nat. Protoc. 17, 2216\u20132239 (2022).","journal-title":"Nat. Protoc."},{"key":"76823_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler, I. J. The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited. Nat. Rev. Cancer 3, 453\u2013458 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"76823_CR41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho, W. J. The tumour microenvironment in pancreatic cancer-clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527\u2013540 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76823_CR42","doi-asserted-by":"publisher","first-page":"2310189","DOI":"10.1002\/adma.202310189","volume":"36","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. ATP-responsive manganese-based bacterial materials synergistically activate the cGAS-STING pathway for Tumor immunotherapy. Adv. Mater. 36, 2310189 (2024).","journal-title":"Adv. Mater."},{"key":"76823_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-72847-1","volume":"17","author":"JJ Liu","year":"2026","unstructured":"Liu, J. J. et al. Disrupting sympathetic nerve-tumor crosstalk via biomimetic nanovesicles to augment chemotherapy efficacy under chronic stress. Nat. Commun. 17, 6230 (2026).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76823-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76823-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76823-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:16:21Z","timestamp":1791933381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76823-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76823"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76823-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10739"}}